Efficacy and Safety of Camrelizumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Phase II Single-Arm Clinical Trial.
Clin Oncol (R Coll Radiol)Jul 11, 2026 (epub)
Y Xiao, L Yang, X Yu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II single-arm trial assessed the efficacy and safety of camrelizumab combined with concurrent chemoradiotherapy in 50 patients with locally advanced cervical cancer. The median progression-free survival (PFS) was not reached, with a 36-month PFS rate of 84.0%. Overall survival (OS) at 36 months was 100%, indicating promising long-term outcomes.
Key findings
- The 36-month progression-free survival rate was 84.0% (95% CI: 73.8-94.2%).
- The 36-month overall survival rate was 100%, with median OS not reached.
- Treatment-related adverse events occurred in 96% of patients, with grade 3 or higher events infrequent (0-18.0%).
- Immune-related adverse events were reported in 92.0% of patients, with 4.0% experiencing grade 3 or higher events.
Why it matters
The study highlights the potential of combining immunotherapy with chemoradiotherapy in improving survival outcomes for patients with locally advanced cervical cancer, a population with limited treatment options.